Tolerability of Postexposure Prophylaxis with Zidovudine, Lamivudine, and Nelfinavir for Human Immunodeficiency Virus Infection | Zendy

Christian Rabaud | Zendy; S Bevilacqua | Zendy; I. Béguinot | Zendy; Véronique Dorvaux | Zendy; H. Schuhmacher | Zendy; T. May | Zendy; P Canton | Zendy

Open Access

Tolerability of Postexposure Prophylaxis with Zidovudine, Lamivudine, and Nelfinavir for Human Immunodeficiency Virus Infection

Author(s) -

Christian Rabaud,

S Bevilacqua,

I. Béguinot,

Véronique Dorvaux,

H. Schuhmacher,

T. May,

P Canton

Publication year - 2001

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/320166

Subject(s) - nelfinavir , tolerability , medicine , zidovudine , lamivudine , adverse effect , post exposure prophylaxis , virology , sida , viral disease , human immunodeficiency virus (hiv) , virus , viral load , antiretroviral therapy , hepatitis b virus

Tolerability of the combination of zidovudine, lamivudine, and nelfinavir used as postexposure prophylaxis (PEP) for HIV infection was prospectively evaluated among 185 patients at 11 hospitals in eastern France. After exclusion of the 106 persons who discontinued PEP either because the source patient subsequently tested HIV seronegative or because the injury was reassessed as resulting in a low risk for transmission of HIV, 67 (85%) of the patients who received such PEP experienced adverse effects, which led to withdrawal of nelfinavir in 28 (35%) of these patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research